NCT01367158 - Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines | Biotech Hunter

Enrollment

440

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

July 31, 2012

Conditions

Meningococcal DiseaseMeningococcal Meningitis

Interventions

BIOLOGICAL

Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine

The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine

BIOLOGICAL

Meningococcal (group B) multicomponent recombinant adsorbed vaccine

Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine

BIOLOGICAL

Tdap

Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection

Trial Locations (7)

Unknown

CESFAM Gabriela Mistral:, Aurora de Chile 9872 - San Ramón

Pontificia Universidad Catolica de Chile, Marcoleta 350

CAFAM, Avenida Carrera 68# 90-88 Piso 4

Centro de Investigacion CafeSalud Medicina Prepagada, Carrera 14 No. 94-49 PisoSexto

Indicasat:, Clayton, Ciudad Del Saber Edificio 219

Health Research International: Centro Especializado san Fernando, Piso Numero 5, Consultorio 12; Via Espana, Las Sabanas,

42A # 17-50

CAIMED, Carrera